2026-07-21T16:29:09Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/178632024-09-21T20:56:57Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc García-Aranda, Marilina author Redondo, Maximino author 2019-05-09 The interaction between programmed cell death protein (PD-1) and its ligand (PD-L1) is one of the main pathways used by some tumors to escape the immune response. In recent years, immunotherapies based on the use of antibodies against PD-1/PD-L1 have been postulated as a great promise for cancer treatment, increasing total survival compared to standard therapy in different tumors. Despite the hopefulness of these results, a significant percentage of patients do not respond to such therapy or will end up evolving toward a progressive disease. Besides their role in PD-L1 expression, altered protein kinases in tumor cells can limit the effectiveness of PD-1/PD-L1 blocking therapies at different levels. In this review, we describe the role of kinases that appear most frequently altered in tumor cells and that can be an impediment for the success of immunotherapies as well as the potential utility of protein kinase inhibitors to enhance the response to such treatments. 10.3390/ijms20092296 1422-0067 International journal of molecular sciences http://hdl.handle.net/10668/13941 31075880 http://hdl.handle.net/20.500.12105/17863 MHC Cancer Checkpoint blockade Immunotherapy Inhibitor Kinase Resistance Tumor escape Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.